MICROLEVLEN ED tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

microlevlen ed tablet blister pack

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; levonorgestrel, quantity: 100 microgram - tablet, sugar coated - excipient ingredients: calcium carbonate; maize starch; povidone; glycol montanate; lactose monohydrate; macrogol 6000; magnesium stearate; sucrose; purified talc - microlevlen ed is indicated for the prevention of pregnancy.

MICROLUT levonorgestrel 30 mcg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

microlut levonorgestrel 30 mcg tablet blister pack

bayer australia ltd - levonorgestrel, quantity: 30 microgram - tablet, sugar coated - excipient ingredients: lactose monohydrate; maize starch; povidone; purified talc; magnesium stearate; sucrose; macrogol 6000; calcium carbonate; glycol montanate - oral contraception

MICROGESTIN FE- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit
MICROGESTIN- norethindrone acetate and eth United States - English - NLM (National Library of Medicine)

microgestin fe- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit microgestin- norethindrone acetate and eth

physicians total care, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - microgestin ® 1/20, microgestin ® fe 1/20 , microgestin ® 1.5/30, and microgestin ® fe 1.5/30 are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease cerebral vascular or coronary artery dise

Microbiological culture media IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

microbiological culture media ivds

media preparation unit, dept microbiology and immunology, the university of melbourne - ct922 - microbiological culture media ivds - culture media for the selection, growth, isolation and/or differentiation of microorganisms including bacteria, yeast and fungi.

FLUTIFORM® PRESSURISED INHALATION SUSPENSION 50 MICROGRAM5 MICROGRAM PER ACTUATION Singapore - English - HSA (Health Sciences Authority)

flutiform® pressurised inhalation suspension 50 microgram5 microgram per actuation

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 50 mcg/actuation - fluticasone propionate 50 mcg/actuation; formoterol fumarate dihydrate 5 mcg/actuation

FLUTIFORM® PRESSURISED INHALATION SUSPENSION 125 MICROGRAM5 MICROGRAM PER ACTUATION Singapore - English - HSA (Health Sciences Authority)

flutiform® pressurised inhalation suspension 125 microgram5 microgram per actuation

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 125 mcg/actuation - fluticasone propionate 125 mcg/actuation; formoterol fumarate dihydrate 5 mcg/actuation

FLUTIFORM® PRESSURISED INHALATION SUSPENSION 250 MICROGRAM10 MICROGRAM PER ACTUATION Singapore - English - HSA (Health Sciences Authority)

flutiform® pressurised inhalation suspension 250 microgram10 microgram per actuation

mundipharma pharmaceuticals pte. ltd. - fluticasone propionate; formoterol fumarate dihydrate - aerosol, metered - 250 mcg/actuation - fluticasone propionate 250 mcg/actuation; formoterol fumarate dihydrate 10 mcg/actuation

MICROGESTIN FE 1/20- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit
MICROGESTIN 1/20- norethindrone aceta United States - English - NLM (National Library of Medicine)

microgestin fe 1/20- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit microgestin 1/20- norethindrone aceta

mayne pharma inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - microgestin and microgestin fe are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table i: lowest expected and typical failure rates during the first year of continuous use of a method % of women experiencing an unintended pregnancy in the first year of continuous use lowest method expected* typical** (no contraception) ...................... (85) (85) oral contraceptives .................... 3 combined ................................ 0.1 n/a*** progestin only ........................ 0.5 n/a*** diaphragm with spermicidal cream or jelly .......................... 6 20 spe

MICROGESTIN FE 1/20- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit United States - English - NLM (National Library of Medicine)

microgestin fe 1/20- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit

rpk pharmaceuticals, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin and microgestin fe are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table i: lowest expected and typical failure rates during the first year of continuous use of a method % of women experiencing an unintended pregnancy in the first year of continuous use lowest method expected* typical** (no contraception) ...................... (85) (85) oral contraceptives .................... 3 combined ................................ 0.1 n/a*** progestin only ........................ 0.5 n/a*** diaphragm with spermicidal cream or jelly .......................... 6 20 spe

MICROGESTIN FE 1.5/30- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit United States - English - NLM (National Library of Medicine)

microgestin fe 1.5/30- norethindrone acetate and ethinyl estradiol and ferrous fumarate kit

rpk pharmaceuticals, inc. - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - microgestin and microgestin fe are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. oral contraceptives should not be used in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - known or suspected carcinoma of the breast - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy or jaundice with prior pill u